AUTHORS
Jason Westin, MD, MS, FACP, FASCO, Georg Lenz, MD2, Marek Trnený, MD, CSc, Prof.3, John M. Burke, MD4, Christopher P. Fox, MD, PhD5, Annalisa Chiappella, MD6, Thomas Witzig, MD7, Christiane Pott, MD8, Philomena Colucci, MD, DO9, Sonia Ioannidis10, Lulu Cheng11, Umberto Vitolo, MD12
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
2 University Hospital Münster, Münster, Germany
3 First Faculty of Medicine Charles University, Prague, Czech Republic
4 Sarah Cannon Research Institute at Rocky Mountain Cancer Centers, Aurora, Colorado, United States
5 Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, University of Nottingham, Nottingham, United Kingdom
6 Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology, Milan, Italy
7 Mayo Clinic, Rochester, Minnesota, United States
8 University Hospital Schleswig-Holstein, Kiel, Germany
9 Incyte Corporation, Wilmington, Delaware, United States
10 Incyte Biosciences International Sàrl, Morges, Switzerland
11 Incyte Corporation, Wilmington, Delaware, United States
12 INOC-Istituto Nazionale Oncologico Candiolo; IRCCS, Candiolo, Turin, Italy
ABSTRACT
Introduction: Approximately 40% of patients (pts) with diffuse large B-cell lymphoma (DLBCL) are not cured by first-line (1L) R-CHOP. Among pts not cured in 1L, primary refractory and early relapsed disease are independent prognostic factors. The phase 3 frontMIND study (NCT04824092) demonstrated a statistically significant 25% reduction in risk of disease progression or death in pts with previously untreated DLBCL with tafasitamab (Tafa) and lenalidomide (Len) added to R-CHOP vs R-CHOP (HR 0.75 [95% CI: 0.59, 0.96]; P=0.0194) (Lenz et al., Lancet 2026). Although overall complete response (CR) rates at EOT were similar, 65.2% in both arms, the rate of overall partial response (PR) at EOT was numerically greater with Tafa-Len-R-CHOP (15.2%) vs R-CHOP (10.9%). Response at EOT is strongly predictive for outcomes; however, PET-PR is challenging as some pts may have residual disease while others may have post-treatment inflammation or other benign reasons for residual FDG avidity. Based on retrospective testing for minimal residual disease (MRD) at EOT with the next-generation sequencing–based EuroClonality cfDNA capture panel, more pts were undetectable with Tafa-Len-R-CHOP (81.3%) vs R-CHOP (66.7%), which suggests that responses may be deeper with the addition of Tafa and Len to R-CHOP. This post hoc analysis aims to characterize PFS in pts with CR and PR by treatment arm, rates of primary refractoriness and early relapse, and clinical outcomes in pts with PET-PR at EOT.
Methods: Pts were 18-80 y with previously untreated, high intermediate- or high-risk DLBCL. Pts were randomized 1:1 to Tafa-Len-R-CHOP or R-CHOP. PET scans were not required after EOT and response could be assessed with CT scans. Kaplan-Meier (K-M) curves for PFS and EFS were generated for pts with CR and PR by treatment arm. Primary refractory disease was defined as stable disease at EOT or progressive disease (PD) at or before EOT, and early relapse was defined as PD within 6 months of EOT. In pts with PET-PR at EOT, subsequent outcomes were categorized as: subsequent spontaneous PET-CR; persistent overall PR with new anti-lymphoma treatment (NALT); persistent overall PR without NALT; and subsequent PD. The rates of the lowest recorded Deauville scores (DS) on PET and the average maximum reduction in the sum of the product of diameters (SPD) on CT scans were also reviewed.
Results: Overall, 899 pts were randomized to Tafa-Len-R-CHOP (n=448) or R-CHOP (n=451). In the Tafa-Len-R-CHOP arm, no notable separation was observed between the PFS K-M curves for pts with PR vs CR at EOT; in the R-CHOP arm, the PFS curve for pts with PR showed an earlier and more pronounced decline than that for pts with CR. Primary refractory disease and early relapse were numerically less frequent with Tafa-Len-R-CHOP, occurring in 6.9% and 5.5%, respectively, compared with 12.6% and 7.5% with R-CHOP, respectively.
Overall, EOT PET-PR was observed in 14.5% (n=65) with Tafa-Len-R-CHOP and 10.4% (n=47) with R-CHOP, respectively; 20.0% (n=13/65) and 19.1% (n=9/47) had a subsequent PET-CR; 26.2% (n=17/65) and 36.2% (n=17/47) had persistent overall PR with NALT; 38.5% (n=25/65) and 19.1% (n=9/47) had persistent overall PR without NALT; and 15.4% (n=10/65) and 25.5% (n=12/47) had subsequent PD. Respective rates of DS4/5 and the average maximum SPD reductions in pts with EOT PET-PR in the Tafa-Len-R-CHOP arm, were 58.8%/41.2% and 86.0% for persistent overall PR with NALT and 88.0%/8.0% and 96.3% for persistent overall PR without NALT. Retrospective MRD data will be presented to add biological insights into these results.
Conclusions: At EOT, PR conferred PFS benefit comparable to CR with Tafa-Len-R-CHOP, but not with R-CHOP. Tafa-Len-R-CHOP resulted in fewer pts with primary refractory and early relapse events than R-CHOP. More pts treated with Tafa-Len-R-CHOP had subsequent CR on PET-CT or persistent overall PR not requiring NALT. DS 4 and a greater reduction in tumor burden on imaging may have informed the decision to not initiate NALT. In the Tafa-Len-R-CHOP arm, the rate of PD after PET-PR at EOT was 10% lower than in the R-CHOP arm. The 25% reduction in the risk of progression or death observed with Tafa-Len -R-CHOP vs R-CHOP, despite comparable EOT CR rates, may reflect an improved quality of response as reflected by better outcomes in pts with PR at EOT and deeper molecular responses as reflected by a higher rate of MRD negativity at EOT with Tafa-Len-R-CHOP vs R-CHOP.
DISCLOSURES
Jason Westin, MD, MS, FACP, FASCO: ADC Therapeutics - Research Funding; Janssen - Research Funding; Allogene Therapeutics - Research Funding; MorphoSys/Incyte Corporation - Research Funding; Nurix - Research Funding; Novartis - Research Funding; Kite/Gilead - Research Funding; Bristol-Myers Squibb - Research Funding; Janssen Scientific Affairs - Research Funding; AstraZeneca - Research Funding; Genentech/Roche - Research Funding; Janssen Scientific Affairs - Consultancy (Includes expert testimony); Lyell Immunopharma - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Chugai Pharma - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Juno - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); MorphoSys/Incyte Corporation - Consultancy (Includes expert testimony); Allogene Therapeutics - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Seagen - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene/Juno - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen Scientific Affairs - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)